奥拉帕利与阿哌沙班之间的药代动力学药物相互作用：一例报告。 - Suppr

Pharmacokinetic drug-drug interaction between olaparib and apixaban: a case report.

作者信息

Berge M, Giraud J S, De Percin S, Puszkiel A, Thomas-Schoemann A, Blanchet B

机构信息

Department of Clinical Pharmacy, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, CARPEM, 75014, Paris, France.

Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, CARPEM, 75014, Paris, France.

出版信息

Cancer Chemother Pharmacol. 2024 May;93(5):519-521. doi: 10.1007/s00280-023-04606-8. Epub 2023 Nov 3.

DOI:10.1007/s00280-023-04606-8

PMID:37921902

Abstract

摘要

相似文献

Pharmacokinetic drug-drug interaction between olaparib and apixaban: a case report.奥拉帕利与阿哌沙班之间的药代动力学药物相互作用：一例报告。

Cancer Chemother Pharmacol. 2024 May;93(5):519-521. doi: 10.1007/s00280-023-04606-8. Epub 2023 Nov 3.

Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban.老年房颤患者服用低剂量阿哌沙班时阿哌沙班高血药浓度的预测因素。

Eur J Clin Pharmacol. 2021 Nov;77(11):1757-1758. doi: 10.1007/s00228-021-03135-8. Epub 2021 May 20.

Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?阿哌沙班和利伐沙班在人母乳中的分布浓度是否具有临床相关性？

Blood. 2020 Oct 8;136(15):1783-1785. doi: 10.1182/blood.2020006231.

Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.药物与阿哌沙班相互作用：文献系统综述及世卫组织自发安全报告数据库（VigiBase）分析。

Pharmacol Res Perspect. 2020 Oct;8(5):e00647. doi: 10.1002/prp2.647.

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.奥拉帕利片剂单药治疗和联合紫杉醇治疗的药代动力学和安全性：中国晚期实体瘤患者的 I 期研究结果。

Cancer Chemother Pharmacol. 2019 May;83(5):963-974. doi: 10.1007/s00280-019-03799-1. Epub 2019 Mar 18.

Clinical Implications of Co-administering Apixaban with Key Interacting Medications.与关键相互作用药物联合使用阿哌沙班的临床意义。

Clin Pharmacol Drug Dev. 2024 Sep;13(9):961-973. doi: 10.1002/cpdd.1446. Epub 2024 Jul 24.

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.奥拉帕利片剂剂型：食物对晚期实体瘤患者口服给药后药代动力学的影响。

Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.

Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.阿哌沙班治疗患者的特征、规定剂量评估及治疗持续性：加泰罗尼亚的一项队列研究

J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):494-501. doi: 10.1177/1074248418778544. Epub 2018 May 23.

Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.每日一次利伐沙班和每日两次阿哌沙班的药代动力学和药效学分离：一项随机交叉研究。

J Thromb Haemost. 2017 Oct;15(10):2017-2028. doi: 10.1111/jth.13801. Epub 2017 Sep 14.

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations.奥拉帕利给药建议的基于生理学的药代动力学建模：桥接制剂、药物相互作用和患者人群。

Clin Pharmacol Ther. 2019 Jan;105(1):229-241. doi: 10.1002/cpt.1103. Epub 2018 Aug 9.

本文引用的文献

Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors.聚ADP-核糖聚合酶抑制剂对转运蛋白外排的抑制作用

Basic Clin Pharmacol Toxicol. 2023 Oct;133(4):428-436. doi: 10.1111/bcpt.13928. Epub 2023 Aug 24.

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation.阿哌沙班血浆水平与出血有关吗？非瓣膜性心房颤动患者出血的临床结局及预测因素。

Biomedicines. 2022 Aug 18;10(8):2001. doi: 10.3390/biomedicines10082001.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.2022 年国际癌症患者静脉血栓栓塞症治疗和预防临床实践指南，包括 COVID-19 患者。

Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7.

Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein.酪氨酸激酶抑制剂和直接口服抗凝剂：P-糖蛋白介导的药物相互作用的体外评价。

Fundam Clin Pharmacol. 2022 Oct;36(5):860-868. doi: 10.1111/fcp.12769. Epub 2022 Feb 28.

Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation.真实世界心房颤动患者中阿哌沙班浓度变异性及其与临床结局的关系。

Sci Rep. 2021 Jul 6;11(1):13908. doi: 10.1038/s41598-021-93372-9.

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.利伐沙班或阿哌沙班与 P-糖蛋白和中度 CYP3A4 抑制剂联合使用的真实世界数据增加了出血风险。

J Thromb Thrombolysis. 2020 May;49(4):636-643. doi: 10.1007/s11239-020-02037-3.

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.阿哌沙班：临床药代动力学和药效学评价。

Clin Pharmacokinet. 2019 Oct;58(10):1265-1279. doi: 10.1007/s40262-019-00775-z.

Clin Pharmacol Ther. 2019 Jan;105(1):229-241. doi: 10.1002/cpt.1103. Epub 2018 Aug 9.

Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study.采用液相色谱/串联质谱法快速测定人血浆中阿哌沙班浓度及其在药代动力学研究中的应用。

J Pharm Biomed Anal. 2013 May 5;78-79:150-3. doi: 10.1016/j.jpba.2013.02.007. Epub 2013 Feb 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetic drug-drug interaction between olaparib and apixaban: a case report.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献